Perspective Therapeutics, Inc.

NYSEAM:CATX Voorraadrapport

Marktkapitalisatie: US$815.2m

Perspective Therapeutics Beheer

Beheer criteriumcontroles 1/4

Perspective Therapeutics' CEO is Thijs Spoor, appointed in Feb 2023, has a tenure of 1.75 years. total yearly compensation is $1.46M, comprised of 34.7% salary and 65.3% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth $250.92K. The average tenure of the management team and the board of directors is 1.7 years and 1.8 years respectively.

Belangrijke informatie

Thijs Spoor

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris34.7%
Dienstverband CEO1.8yrs
Eigendom CEO0.03%
Management gemiddelde ambtstermijn1.7yrs
Gemiddelde ambtstermijn bestuur1.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Thijs Spoor's beloning veranderd ten opzichte van Perspective Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$52m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$1mUS$506k

-US$37m

Compensatie versus markt: Thijs's total compensation ($USD1.46M) is below average for companies of similar size in the US market ($USD3.24M).

Compensatie versus inkomsten: Insufficient data to compare Thijs's compensation with company performance.


CEO

Thijs Spoor (52 yo)

1.8yrs

Tenure

US$1,458,996

Compensatie

Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Johan Spoor
CEO & Director1.8yrsUS$1.46m0.031%
$ 250.9k
Jonathan Hunt
CFO and Principal Financial & Accounting Officer5.9yrsUS$1.17m0.053%
$ 434.9k
Markus Puhlmann
Chief Medical Officer1.8yrsUS$900.09k0.20%
$ 1.7m
Shane Cobb
Executive Vice President of Operations1.3yrsgeen gegevensgeen gegevens
Michael Schultz
Chief Science Officerno datageen gegevens2.2%
$ 17.9m
Annie Cheng
Vice President of Investor Relationsno datageen gegevensgeen gegevens
Andrew Bright
Executive Vice President of Brachytherapy1.6yrsgeen gegevensgeen gegevens
Amos Hedt
Chief Business Strategy Officerno datageen gegevensgeen gegevens
Frances Johnson
Chief Innovation Officerno datageen gegevens2.2%
$ 17.9m
David Hauser
Senior Vice President of Clinical Operationsno datageen gegevensgeen gegevens
Steve Keefe
Senior Vice President of Clinical Developmentless than a yeargeen gegevensgeen gegevens

1.7yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren management: CATX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Johan Spoor
CEO & Director1.8yrsUS$1.46m0.031%
$ 250.9k
Robert Williamson
Independent Director1.8yrsUS$320.06k0.063%
$ 516.8k
Frank Morich
Independent Director1.8yrsUS$320.06kgeen gegevens
Heidi Henson
Independent Director1.4yrsUS$390.70kgeen gegevens
Lori Holmes-Woods
Chairperson of the Board6.4yrsUS$671.73k0.24%
$ 2.0m

1.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: CATX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.